Baird Maintains Outperform on Cardinal Health, Raises Price Target to $130
$CAH
Other Pharmaceuticals
Health Care
Baird analyst Eric Coldwell maintains Cardinal Health (NYSE:CAH) with a Outperform and raises the price target from $129 to $130.
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/26/2024 | $125.00 | Outperform | Leerink Partners |
| 2/9/2024 | Hold → Buy | Argus | |
| 1/3/2024 | $117.00 | Overweight | Barclays |
| 12/14/2023 | $96.00 | Underweight | Wells Fargo |
| 7/10/2023 | $100.00 | Outperform → In-line | Evercore ISI |
| 3/31/2023 | $77.00 | Neutral | Citigroup |
| 2/3/2023 | $87.00 → $94.00 | Neutral → Outperform | Robert W. Baird |
| 11/4/2022 | $64.00 → $80.00 | Underperform → Neutral | BofA Securities |
8-K - CARDINAL HEALTH INC (0000721371) (Filer)
424B5 - CARDINAL HEALTH INC (0000721371) (Filer)
FWP - CARDINAL HEALTH INC (0000721371) (Subject)
DUBLIN, Ohio, Feb. 28, 2024 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors has elected Robert "Bob" Azelby as an independent director, effective March 1. Mr. Azelby joins the board with over 30 years of experience, including as a Chief Executive Officer and board member for large, matrixed organizations in the biopharmaceutical, oncology and other specialty industries. Mr. Azelby has previously served as President and Chief Executive Officer of Eliem Therapeutics, and prior to Eliem, he was the Chief Executive Officer of Alder BioPharmac
Revenue increased 13% to $49.6 billionGAAP1 operating earnings were $137 million, GAAP diluted EPS were $0.40Non-GAAP operating earnings decreased 20% to $423 million due to a decline in Medical segment profit, partially offset by an increase in Pharmaceutical segment profit; non-GAAP diluted EPS decreased 7% to $1.20Company reaffirmed fiscal year 2023 non-GAAP EPS guidanceDUBLIN, Ohio, Nov. 4, 2022 /PRNewswire/ -- Cardinal Health (NYSE:CAH) today reported first quarter fiscal year 2023 revenues of $49.6 billion, an increase of 13% from the first quarter of last year. First quarter GAAP operating earnings were $137 million, including a non-cash, pre-tax goodwill impairment charge of $154 mil
Adds Four New Independent Directors to the Board Forms New Business Review Committee to Evaluate Portfolio and Operations DUBLIN, Ohio, Sept. 6, 2022 /PRNewswire/ -- Cardinal Health (NYSE:CAH) today announced initiatives aimed at positioning the Company for long-term success, building on Cardinal Health's previously announced growth plans. These initiatives have benefited from input received from Elliott Investment Management L.P. ("Elliott"). In connection with these initiatives, Elliott has also entered into a cooperation agreement with Cardinal Health, and Elliott's Steven Barg will join the Company's Board of Directors.
Citigroup analyst Daniel Grosslight maintains Cardinal Health (NYSE:CAH) with a Neutral and lowers the price target from $115 to $107.
Cardinal Health's (NYSE:CAH) short percent of float has fallen 17.69% since its last report. The company recently reported that it has 6.12 million shares sold short, which is 3.35% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.18 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short intere
Evercore ISI Group analyst Elizabeth Anderson maintains Cardinal Health (NYSE:CAH) with a In-Line and lowers the price target from $115 to $105.
DUBLIN, Ohio, Nov. 5, 2024 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors approved a quarterly dividend of $0.5056 per share out of the Company's capital surplus. The dividend will be payable on January 15, 2025 to shareholders of record at the close of business on January 2, 2025. About Cardinal HealthCardinal Health is a distributor of pharmaceuticals and specialty products; a global manufacturer and distributor of medical and laboratory products; a supplier of home-health and direct-to-patient products and services; an operator of nuc
Revenue decreased 4% to $52.3 billion; revenue increased 15% excluding the impact of the previously communicated large customer contract expirationGAAP1 operating earnings were $568 million; GAAP diluted EPS was $1.70Non-GAAP operating earnings increased 12% to $625 million, driven by significant growth in Pharmaceutical and Specialty Solutions segment profitNon-GAAP diluted EPS increased 9% to $1.88Fiscal year 2025 non-GAAP EPS guidance2 raised to $7.75 to $7.90, from $7.55 to $7.70DUBLIN, Ohio, Nov. 1, 2024 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today reported first quarter fiscal year 2025 revenue of $52.3 billion, a decrease of 4% from the first quarter of fiscal year 2024. First qu
DUBLIN, Ohio, Aug. 15, 2024 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors approved a quarterly dividend of $0.5056 per share out of the Company's capital surplus. The dividend will be payable on October 15, 2024 to shareholders of record at the close of business on October 1, 2024. About Cardinal HealthCardinal Health is a distributor of pharmaceuticals, a global manufacturer and distributor of medical and laboratory products, and a provider of performance and data solutions for healthcare facilities. With more than 50 years in business
SC 13G/A - CARDINAL HEALTH INC (0000721371) (Subject)
SC 13G/A - CARDINAL HEALTH INC (0000721371) (Subject)
SC 13G/A - CARDINAL HEALTH INC (0000721371) (Subject)
4 - CARDINAL HEALTH INC (0000721371) (Issuer)
4 - CARDINAL HEALTH INC (0000721371) (Issuer)
4 - CARDINAL HEALTH INC (0000721371) (Issuer)
Next generation of the Kendall™ SCD Series delivers an all-in-one solution for deep vein thrombosis and pulmonary embolism prevention DUBLIN, Ohio, Nov. 20, 2024 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today the U.S. launch of its Kendall SCD SmartFlow™ Compression System, the next generation of the Kendall™ Compression Series offering an enhanced clinician and patient experience. Featuring clinically proven technology that delivers customized, intermittent pneumatic compression (IPC) to increase blood flow1 in at-risk patients, the Kendall SCD SmartFlow™ System is designed to help prevent venous thromboembolism (VTE) events, as well as enhance blood circulation and treat pain a
Cardinal Health to acquire Advanced Diabetes Supply Group Court Square Capital Partners ("Court Square"), a leading middle-market private equity company, announced today it has entered a definitive agreement in the sale of Advanced Diabetes Supply® Group ("ADSG", or "Company") to Cardinal Health (NYSE:CAH). Court Square originally acquired the Company in December 2020. Headquartered in Carlsbad, CA, ADSG is a national distributor of Durable Medical Equipment ("DME") specializing in diabetes supplies. The Company currently serves approximately 500,000 patients and specializes in the home delivery of diabetes products including continuous glucose monitoring ("CGM") devices and other testi
Southlake, Texas, Nov. 11, 2024 (GLOBE NEWSWIRE) -- GI Alliance (GIA) announced today that it has entered into a definitive agreement with Cardinal Health (NYSE:CAH) through which Cardinal Health will acquire a majority stake in GIA, a physician-led, national management services organization supporting independent gastroenterology practices from a combination of GIA physician owners and funds managed by affiliates of Apollo (NYSE:APO). The transaction values GI Alliance at $3.9 billion. "GI Alliance and Cardinal Health are aligned in our shared vision to build a physician-led, national specialty healthcare platform that will be the preferred choice for patients seeking dependable, high
Leerink Partners initiated coverage of Cardinal Health with a rating of Outperform and set a new price target of $125.00
Argus upgraded Cardinal Health from Hold to Buy
Barclays initiated coverage of Cardinal Health with a rating of Overweight and set a new price target of $117.00